OIE Reference Laboratory Reports Activities

Activities in 2015

This report has been submitted : 2016-01-18 05:37:24

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Highly and low pathogenic avian influenza
Address of laboratory:	5 Portarlington Road Private Bag 24 Geelong, Victoria 3220 AUSTRALIA
Tel.:	+61-3 52 27 50 00
Fax:	+61-3 52 27 55 55
E-mail address:	frank.wong@csiro.au
Website:	www.csiro.au
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Kurt Zuelke -Director
Name (including Title and Position) of OIE Reference Expert:	Dr Frank Wong- Team Leader – DSR AAHL
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
C-ELISA	YES	1672	652
HI	YES	6	148
Direct diagnostic tests		Nationally	Internationally
Real time PCR	YES	5986	2776
PCR and sequencing	YES	64	114
Isolation	YES	293	66
IHC	No	9	0

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
Influenza A Matrix Real-time PCR Assay Primer and Probe KIT for 500 tests	Influenza A Matrix real-time PCR	Provide	0	72kits	11	☒Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Influenza A Matrix Conventional PCR Assay Primer and Probe KIT for 500 tests	Influenza A Matrix conventional PCR	Provide	0	1 kit	1	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Influenza A H7 Real-time PCR Assay Primer and Probe KIT for 500 tests	Influenza A FLI-H7 real-time PCR	Provide	17 kits	29 kits	>8	☒Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Influenza A N9 Real-time PCR Assay Primer and Probe KIT for 500 tests	Influenza A CNIC-N9 real-time PCR	Provide	0	12 kits	8	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Influenza A H5 real-time PCR Assay Primer and Probe KIT for 500 tests	Influenza A H5 real-time PCR	Provide	0	30 kits	8	☒Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East

Influenza A H5 2.3.4.4 (H5N6) real-time PCR Assay Primer and Probe KIT for 500 tests	Influenza A H5 (H5N6) real-time PCR	Provide	0	9 kits	8	☒Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Influenza A H9 real-time PCR Assay Primer and Probe KIT for 500 tests	Influenza A H9 real-time PCR	Provide	0	24 kits	9	☒Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Influenza A N1 real-time PCR Assay Primer and Probe KIT for 500 tests	Influenza A N1 real-time PCR	Provide	0	10 kits	8	☒Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Influenza A N2 conventional PCR Assay Primer and Probe KIT for 500 tests	Influenza A N2 conventional PCR	Provide	0	12 kits	6	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Influenza A N6 real-time PCR Assay Primer and Probe KIT for 500 tests	Influenza A N6 real-time PCR	Provide	0	9 kits	>5	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
PCR Quality Assurance controls for Influenza A (High, Low & Negative Extraction Controls - Kit - 3 x 1ml)	Influenza A real-time PCR (Matrix and H-types)	Produced	31ml	43 kits (95ml)	6	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East

PCR Quality Assurance controls for Influenza A (High, Low & Negative Extraction Controls – Kit – 3 x 1ml)	Influenza A real-time PCR (N-types)	Produced	0	12 kits (30ml)	3	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
PCR Quality Assurance controls for Influenza A (High, Low & Negative Extraction Controls – Kit – 3 x 1ml)	Influenza A real-time PCR (Matrix, H5N1, H7N9, H9N2)	Produced	0	9 kits (30ml)	3	☒Africa ☐Americas ☐Asia and Pacific ☐Europe ☐Middle East
Influenza A H5 Antigen	Influenza A haemagglutination inhibition test antigen	Produced	0	168ml	>8	☐Africa ☐Americas ☒Asia and Pacific ☒Europe ☐Middle East
Influenza A H5 antiserum	For Haemagglututination Inhibition tests	Produced	0	123ml	>8	☐Africa ☒Americas ☒Asia and Pacific ☒Europe ☐Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
MYANMAR	March	0	6
VIETNAM	March	25	0
PAPUA NEW GUINEA	April	63	0
MYANMAR	June	0	4
TIMOR-LESTE	August	114	0
MYANMAR	Septmember	200	0
LAOS	November	0	3

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
INDONESIA	Facilitation and implementation of development of the Influenza Virus Monitoring(IVM) platform IVM online and provision of related laboratory support and training in Indonesia	In loco
THAILAND	ASEAN Countries - Backstopping mission to participating laboratories in emergency surveillance and response in multi-disease training production	In loco
INDONESIA	Technical review and support for various diseases for the project; Australian Indonesia partnership for Emerging Infectious Diseases	in loco

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)
Surveillance tools and strategies for improved control, monitoring and eradication of Avian Influenza in Indonesia	3.5 years	Collaboration project to provide surveillance tools and strategies for the improved control, monitoring and eradication of avian influenza in Indonesia	University of Melbourne Veterinary School and the Indonesia national Disease investigation Centers
Facilitation and implementation of development of the Influenza Virus Monitoring(IVM) platform IVM online and provision of related laboratory support and training in Indonesia	1 year	AAHL provides technical assistance to a USAID (FAO) supported project fostering the development of a molecular surveillance information management system, “IVM Online”, to detect and monitor the development of variants of the H5N1 HPAI virus. The IVM Online is an advanced national data management and analysis platform that was formally launched in Indonesia during 2014, with a phase of enhancements during 2015.	FAO/OFFLU

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 10
1. Grillo, Victoria; Arzey, K E; Hansbro, Philip; Hurt, Aeron; Warner, S; Bergfeld, Jemma; et al. Avian influenza in Australia: a summary of 5 years of wild bird surveillance. Australian Veterinary Journal. 2015; 93(11):387-393.

2. Hartaningsih, Nining; Wibawa, Hendra; Pudjiatmoko, Pak; Sumping Tjatur Rasa, Fadjar; Irianingsih, Sri Handayani; Dharmawan, Rama; Azhar, Muhammad; Sawitri, Elly; McGrane, James; Wong, Frank; Selleck, Paul; Allen, John; Broz, Ivano; Torchetti, Mia Kim; Dauphin, Gwenaelle; Claes, Filip; Sastraningrat, Wiryadi; Durr, Peter. Surveillance at the molecular level: developing an integrated network for detecting variation in avian influenza

viruses in Indonesia.. Preventive Veterinary Medicine. 2015; 120(1):96-105.

3. Heine, Hans; Foord, Adam; Wang, Jianning; Valdeter, Stacey; Walker, Som; Morrissy, Chris; et al. Detection of highly pathogenic zoonotic influenza virus H5N6 by reverse-transcriptase quantitative polymerase chain reaction. Virology Journal. 2015; 12(18 1):1-4.

4. Hyatt, Alex; Aguirre, Alonso; Jeggo, Martyn; Woods, Rupert. Effective Coordination and Management of Emerging Infectious Diseases in Wildlife Populations. EcoHealth. 2015; 12(3):408-411.

5. Mohr, Peter; Deng, Yi-Mo; McKimm-Breschkin, Jenny. The neuraminidases of MDCK grown human influenza A (H3N2) viruses isolated since 1994 can demonstrate receptor binding. Virology Journal. 2015; 12(67):1-11.

6. Swayne, David; Suarez, David; Spackman, Erica; Jadhao, Samadhan; Dauphin, Gwenaelle; Kim-Torchetti, Mia; et al. Antibody Titer Has Positive Predictive Value for Vaccine Protection against Challenge with Natural Antigenic Drift Variants of H5N1 High Pathogenicity Avian Influenza Viruses from Indonesia. Journal of Virology. 2015; 89(7):3746-3762.

7. Tarigan S, Indriani R, Durr PA, Ignjatovic J. Characterization of the M2e antibody response following highly pathogenic H5N1 avian influenza virus infection and reliability of M2e ELISA for identifying infected among vaccinated chickens. 2015. Avian Pathol. 27:1-40.

8. Wong, Frank; Phommachanh, Phouvong; Kalpravidh, Wantanee; Chanthavisouk, Chintana; Gilbert, Jeff; Bingham, John; et al. Reassortant Highly Pathogenic Avian Influenza H5N6 Virus in Laos. Emerging Infectious Diseases. 2015; 21(3):511-516.

9. Nuradji, Harimurti; Bingham, john; Lowther, Sue; Wibawa, Hendra; Colling, Axel; Thanh Long, Ngo; Meers, Joanne. A comparative evaluation of feathers, oropharyngeal swabs, and cloacal swabs for the detection of H5N1 highly pathogenic avian influenza virus infection in experimentally infected chickens and ducks. Journal of Veterinary Diagnostic Investigation. 2015 Vol 27(6) 704-715.

10. WHO/OIE/FAO H5 Evolution Working Group. 2015 Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013–2014. Influenza and Other Respiratory Viruses. 9(5):271–276.

b) International conferences: 3

1. Durr, Peter; Broz, Ivano; Graham, Kerryne; Wang, Jianning; Wong, Frank; McCullough, Sam. Next Generation Surveillance Systems – integrating whole genome sequencing data into real-time detection and control (of TADs / EADs). In: International Symposium of the World Association of Veterinary Laboratory Diagnosticians; 17th June 2015; Saskatoon, Canada.

2. Wong, Frank; Claes, Filip; Cattoli, Giovanni. Overview of OFFLU contribution to WHO Influenza Vaccine Composition Meetings for 2012–2014. In: OFFLU Technical Meeting 2015; 15 April 2015; Athens, Georgia, USA. OFFLU; 2015. 1.

3. Wong, Frank; Stevens, Vicky; Dauphin, Gwenaelle. Tracking Genetic Evolution of Avian Influenza Viruses and Related Challenges. In: International Symposium of the World Association of Veterinary Laboratory Diagnosticians; 15-18 June 2015; Saskatoon, Canada. WAVLD; 2015. 1.

c) National conferences: 2

1. Wong F, Morrissy M, Claes F. OIE/FAO regional update on zoonotic influenza in animals. 10th Australian Influenza Symposium. Melbourne, Australia, 12-13 November 2015.

2. Butler J, Stewart CR, Layton DS, Shan S, Harper J, Payne J, Valdeter S, Walker S, Harvey G, Bruce MP, Rootes CL, Gough TJ, Rohringer A, Fardy SJ, Karpala AJ, Johnson D, Wang J, Wong FYK, Bean AGD, Williams DT, and Bingham J. Pathobiology and immunological responses in chickens infected with influenza A/Duck/Laos/XBY004/2014 (H5N6), a new reassortant highly pathogenic avian influenza type. 10th Australian Influenza Symposium. Melbourne, Australia, 12-13 November 2015.

d) Other:
(Provide website address or link to appropriate information) 5

http://www.offlu.net/index.php?id=318&L=%2Fproc%2Fself%2Fenviron%27A%3D0
http://www.who.int/influenza/vaccines/virus/201502_zoonotic_vaccinevirusupdate.pdf
http://www.who.int/influenza/vaccines/virus/201509_zoonotic_vaccinevirusupdate.pdf
http://www.oie.int/en/animal-health-in-the-world/update-on-avian-influenza/2015/
http://www.who.int/influenza/gisrs_laboratory/h5n1_nomenclature/en/

Books/Book chapters
1. Daniels, Peter; Edwards, Steve. Management of Veterinary Laboratories. In: OIE, editor/s. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2015. OIE Terrestrial Manual 2015: OIE; 2015. 1-8.

Reports/Report Chapters
1. Morrissy, Chris. Final Report on Production of Ferret Serum against Selected Animal Influenza Viruses. Association of Public Laboratories (APHL) Project, Agreement 2015020474. December 2015.

2. Wong, Frank. OFFLU Summary Report on the World Health Organization Vaccine Consultation Meetings for the Northern Hemisphere, February and Southern Hemisphere, September 2015. December 2015 (OFFLU website).

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 65
b) Seminars: 40
c) Hands-on training courses: 54
d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
B	Indonesia	65
A	Indonesia	40
C	ASEAN countries	54

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System certified according to an International Standard?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO 17025	ED 2012 884 ISO QA Certification ISO 17025- NATA Accredited Laboratory Certifica....pdf
ISO 9001:2008	ED 2013 16882 AAHL Quality Assurance (QA) - Certification of Registrati....pdf
ISO 17043	ISO 17043 13546 20418 cert (2).pdf

16. Is your laboratory accredited by an international accreditation body?

Yes

Test for which your laboratory is accredited	Accreditation body
20.10 Microbiology For companion animals, production animals, production avian species, zoo animals, wildlife, aquatic animals, equine species and avian species	NATA (ILAC affiliated)
20.11 Bacteriology 01 Diagnostic bacteriology - incorporating identification by simple microscopy, cultural methods of detection and identification of organisms 03 Immunological methods of antigen detection	NATA (ILAC affiliated)
20.13 Other Microorganisms 01 Diagnostic microbiology - incorporating identification by simple microscopy, cultural methods of detection and identification of organisms, including Innocuity testing	NATA (ILAC affiliated)
20.14 Virology 01 Diagnostic virology - non-cultural (immunological) methods of detection 02 Diagnostic virology - cultural methods of detection and identification of organisms Including Innocuity testing 05 Quantitative procedures	NATA (ILAC affiliated)
20.15 Prions 01 Histological identification of prion disease lesions 02 Detection of prion protein by immunological methods (including ELISA, Western Blots, immunohistochemistry) 04 Detection of prion protein by bioassay	NATA (ILAC affiliated)
20.25 Serology of Infection For companion animals, production animals, production avian species, zoo animals, wildlife, equine species and avian species 01 Agar gel immunodiffusion tests 02 Complement fixation tests 03 Enzyme linked immunosorbent assays 04 Haemagglutination inhibition 05 Indirect fluorescent antibody tests 06 Microscopic agglutination tests 08 Serum agglutination tests 09 Serum neutralisation tests 10 Latex agglutination tests 99 Other - Testing for rabies and rabies related lyssaviruses on human specimens	NATA (ILAC affiliated)
20.50 Anatomical Pathology For companion animals, production animals, production avian species, laboratory animals, zoo animals, wildlife, aquatic animals, equine species and avian species	NATA (ILAC affiliated)
20.52 Histopathology 01 Processing of fixed specimens for histology 04 Immunohistochemistry 05 Histological interpretation	NATA (ILAC affiliated))
20.53 Electron Microscopy 01 Transmission electron microscopy 02 Scanning electron microscopy 04 Immunohistochemistry electron microscopy	NATA (ILAC affiliated)
20.54 Necropsy	NATA (ILAC affiliated)
20.80 Molecular Diagnostics For companion animals, production animals, production avian species, aquatic animals, equine species and avian species 01 Identification by extraction and amplification 02 Sequencing 03 Genotyping 99 Other - Testing for rabies and rabies related lyssaviruses on human specimens by molecular techniques	NATA (ILAC affiliated)
20.95 Foreign Regulatory Requirements 01 European Union Directives for Animal Health Council Directive 88/407/EEC of 14 June 1988 Council Directive 64/432/EEC of 26 June 1964 Commission Implementing Decision 2011/630/EU of 20 September 2011 Council Directive 89/556/EEC of 25 September 1989 Commission Decision 2006/168/EC of 4 January 2006 Council Directive 91/68/EEC of 28 January 1991 Council Directive 92/65/EEC of 13 July 1992 Commission Decision 2010/472/EU of 26 August 2010 Commission Decision 2004/211/ED of 6 January 2004 Commission Decision 2010/471/EU of 26 August 2010 For the following species for the following diseases using the following methods of testing: Ovine - EHD, c-ELISA, SNT	NATA (ILAC affiliated)
1.12 Weighing devices [In-House Calibration] 01 Precision laboratory balances [In-House Calibration] with least uncertainties of measurement of - 5 in 10^6 or 56 µg (whichever is greater) up to 3 kg	NATA (ILAC affiliated)

1.80 Calibration of temperature measuring equipment [In-House Calibration] 41 Digital temperature indicator systems [In-House Calibration] with least uncertainties of measurement of - 0.5ºC from -20 to 125ºC	NATA (ILAC affiliated)
1.84 Testing of controlled enclosures [In-House Calibration] 02 Incubators [In-House Calibration] with least uncertainties of measurement of - 0.5ºC from 0 to 125ºC by the methods of - AS 2853 03 Autoclaves and sterilising ovens [In-House Calibration] with least uncertainties of measurement of - 0.5ºC from 0 to 125ºC	NATA (ILAC affiliated)
13.69 Controlled environments [In-House Calibration] by the methods of - AS 1807.1, .5, .6, .22, .23 AS/NZS 2243.8 Appendices A and B 01 Clean rooms and workstations [In-House Calibration] .02 Biological safety cabinets [In-House Calibration] .03 Fume cupboards [In-House Calibration]	NATA (ILAC affiliated)
Accreditation No: 13546 (Scope Last Changed 08/12/14)	NATA (ILAC affiliated)

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2014, Chapter 1.1.3a)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
11th OIE Seminar New Diagnostic Technologies and International Standard Setting	June 2015	Canada	Invited attendee/speaker	Genetic Evolution of Avian Influenza and Related Challenges
WHO consultation on the composition of Influenza vaccines for the northern Hemisphere	Feb 2015	Geneva	Speaker	OFFLU Laboratory Network overview on Zoonotic Influenza
WHO consultation on the composition of Influenza vaccines for the Southern Hemisphere	Sept 2015	Geneva	Speaker	OFFLU Laboratory Network overview on Zoonotic Influenza
OFFLU	April 2015	USA	invited attendees	Coordination of the science underpinning the management and control of influenza in animals
9th ISAI Scientific Program	April 2015	USA	Invited attendee/speaker	HPAI Outbreaks in Australia: H7N2 and H7N7
OFFLU Swine Influenza Group Meeting for the coordinated global influenza surveillance in pigs	Dec 2015	France	Speaker	Coordinated global influenza surveillance in pigs

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests:[1]	Role of your Reference Laboratory (organiser/ participant)	No. participants	Participating OIE Ref. Labs/ organising OIE Ref. Lab.
Harmonisation of diagnostic testing for AI among international reference centres	Participant	2	USDA, Ames, Iowa; FLI Germany

[1] *validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.*

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
International preparedness for zoonotic influenza: H7N9, H5N8 and H5N6	Data sharing, analysis and recommendations on diagnosis and surveillance testing	The OFFLU network
WHO consultation on the composition of Influenza vaccines for pandemic preparedness	Data sharing, analysis and recommendations on vaccine seeds for zoonotic and pandemic influenza preparedness	The OFFLU network
WHO/OIE/FAO H5 Evolution and Nomenclature	Data sharing, analysis and recommendations on H5 HPAI nomenclature, evolution and surveillance	The OFFLU network
Global swine influenza surveillance	Data sharing, analysis and recommendations on SIV evolution, antigenic and genetic surveillance, and nomenclature	The OFFLU network
OFFLU Influenza in Wildlife	Data sharing, analysis and recommendations on diagnosis and surveillance testing of emergent influenza subtypes in wildlife	The OFFLU network
H9N2 evolution and nomenclature	Data sharing, analysis and recommendations on H9N2 nomenclature, evolution and surveillance	The OFFLU network

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

Purpose for inter-laboratory test comparisons[1]	No. participating laboratories	Region(s) of participating OIE Member Countries
Harmonising existing test methods specify: PCR Influenza A Proficiency testing	9	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Harmonising existing test methods specify: ELISA Influenza A	7	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East
Harmonising existing test methods specify: PCR Influenza A Proficiency testing	15	☐Africa ☐Americas ☒Asia and Pacific ☐Europe ☐Middle East

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
Ad hoc group	OIE HQ, Paris	High throughput sequencing and bioinformatics
OIE PVS Pathway Laboratory tool training and mission	Mongolia and Australia	OIE PVS Laboratory Tool training and mission execution
2015 Regional Animal Health Laboratory Technical Advisory group (lab- TAG) Meeting	Thailand	Regional coordination for technical advice to the member countries on strategic planning and laboratory capacity building activities related to emerging, re-emerging and priority animal diseases of the region.

25. Additional comments regarding your report:

Please include into question number 3 - template did not have facility to add additional lines

- Influenza A H7 Antigen:Influenza A haemagglutination inhibition test antigen- Produced 25 ml for 3 countries- Europe and Asia/Pacific

- Influenza A H7 antiserum for Haemagglututination Inhibition tests: Produced 5ml for 2 countries - Asia and pacific

- Influenza A H9 Antigen Influenza A haemagglutination inhibition test antigen: Produced 3 ml for 1 country in Asia and pacific

- Influenza A H9 antiserum for Haemagglututination Inhibition tests: Produced 2ml for 2 countries Asia and pacific

- Influenza A blocking ELISA kit Blocking ELISA for the detection of antibodies to Avian Influenza A virus in various sera: Produced 4 kits for 2 countries - Asia and pacific